RIGEL PHARMACEUTICALS INC: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 10 November 2026, by SEC EDGAR SCHEDULE 13G
30
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp has disclosed a stake exceeding 5% in Rigel Pharmaceuticals Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000717). The passive institutional position signals renewed big-fund interest in the small-cap biotech. Investors will watch for further 13G/13D updates and Rigel's next earnings or pipeline disclosures for clues on whether the stake grows.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
State Street Corp, Rigel Pharmaceuticals Inc